invest1 publisher
Xenon's $5.9 billion market value already prices the epilepsy filing
Azetukalner beat placebo by 42.8 points at the Phase 3 high dose and the FDA filing is due this quarter, yet a Seeking Alpha analyst values Xenon at $62 against a $59 price and rates it a Hold.
Publishers:seekingalpha.com
Reality
- Evidence28
- Adoption
- Insufficient
- Hype gap−12
- Incentives32
- Confidence34